J. Bliesath

发表

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

D. V. Von Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012, Molecular Cancer Therapeutics.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

R. Hannan, M. Bywater, E. Sanij, 2011, Cancer research.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2010, Cancer research.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Carleen Cullinane, Ricky W Johnstone, S. Lowe, 2012, Cancer cell.

Structural and biochemical characterization of the therapeutic Anabaena variabilis phenylalanine ammonia lyase.

R. Stevens, E. Abola, P. Fitzpatrick, 2008, Journal of molecular biology.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Journal of medicinal chemistry.

341 POSTER CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity

J. Bliesath, Caroline B. Ho, K. Anderes, 2008 .

Therapeutics , Targets , and Chemical Biology CX-4945 , an Orally Bioavailable Selective Inhibitor of Protein Kinase CK 2 , Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Brien, Adam Siddiqui-Jain, J. Bliesath, 2010 .

A more efficient RNAi inducible system for tight regulation of gene expression in mammalian cells and xenograft animals.

Demin Zhou, F. Wong-Staal, Qi-xiang Li, 2007, RNA.

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Molecular and Cellular Biochemistry.

Preclinical Development CK 2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Ef fi cacy : Mechanistic Rationale for Drug Combination Therapy

D. V. Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012 .

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

Amy Lin, D. V. Von Hoff, Adam Siddiqui-Jain, 2009, Cancer research.

A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: identifying the receptors involved in amyloid beta degradation.

K. Rhoades, F. Wong-Staal, J. Bliesath, 2006, Genomics.

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, Cancer letters.

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Biochemical and biophysical research communications.

A method for detecting and preventing negative RNA interference in preparation of lentiviral vectors for siRNA delivery.

Demin Zhou, F. Wong-Staal, J. Bliesath, 2009, RNA.

Generation of shRNA Pool Library: A Revision of the Biological Technique from the Viewpoint of Chemistry

Demin Zhou, F. Wong-Staal, Li-he Zhang, 2008, Chembiochem : a European journal of chemical biology.

A 96-well surrogate survival assay coupled with a special short interfering RNA vector for assessing cancer gene targets with enhanced signal/noise ratio and its utility in HTS for cancer therapeutic targets.

F. Wong-Staal, J. Bliesath, N. Ke, 2005, Assay and drug development technologies.

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Adam Siddiqui-Jain, J. Bliesath, Diwata Macalino, 2012, ACS medicinal chemistry letters.

Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia.

H. Monenschein, A. Amador-Arjona, J. Bliesath, 2021, Journal of medicinal chemistry.

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Adam Siddiqui-Jain, J. Bliesath, Nicole Streiner, 2010 .

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

S. Lowe, C. Schmitt, R. Pearson, 2012, Cancer cell.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Generation of shRNA Pool Library: A Revision of the Biological Technique from the Viewpoint of Chemistry

Demin Zhou, F. Wong-Staal, Li-he Zhang, 2008, Chembiochem : a European journal of chemical biology.